dr. ramalingam on the role of osimertinib in egfr t790m-positive advanced nsclc
Published 7 years ago • 664 plays • Length 1:40Download video MP4
Download video MP3
Similar videos
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
2:04
dr. suresh ramalingam on frontline osimertinib data in egfr nsclc
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
1:45
dr. ramalingam on the use of osimertinib in clinical trial and real-world settings
-
3:59
osimertinib for egfr t790m resistance mutations in nsclc
-
5:45
osimertinib in t790m-mutant lung cancer
-
1:05
dr. ramalingam on the activity of osimertinib combinations in nsclc
-
9:49
osimertinib as frontline therapy for egfr-positive nsclc
-
1:19
dr. ramalingam on the significance of the flaura trial in nsclc
-
6:50
osimertinib: a potential new standard of care for advanced egfr-mutated nsclc | suresh ramalingam
-
3:13
osimertinib responses after rociletinib treatment of t790m-positive nsclc
-
6:22
osimertinib’s role in egfr metastatic lung cancer
-
1:31
dr. gold on the future of osimertinib in lung cancer
-
5:29
osimertinib for the t790m resistance mutation
-
2:34
dr. ramalingam on flaura findings in egfr-mutant nsclc
-
5:20
rociletinib/osimertinib for egfr t790m-negative nsclc
-
10:20
role of adjuvant osimertinib in early stage nsclc
-
0:56
dr. ramalingam on treatment parameters for osimertinib in lung cancer
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer